08:29 AM EST, 03/05/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Wednesday it is offering cash-paying patients all dose strengths of Wegovy at a lower price of $499 per month through a direct-to-patient delivery option called NovoCare Pharmacy.

The company said NovoCare Pharmacy expands its offerings to meet the needs of people living with obesity, following the recent decision of the US Food and Drug Administration that the shortage of the medicine has been resolved.

Uninsured patients or eligible patients with commercial insurance who don't have coverage for obesity medicines can avail of the offer, the company said.